

165. Synthesis of 4'-C-Acylated Thymidines



by Andreas Marx, Peter Erdmann, Martin Senn, Steffi Körner, Tobias Jungo, Mario Petretta,
Petra Imwinkelried, Adrian Dussy, Klaus J. Kulicke, Ludwig Macko, Margareta Zehnder, and Bernd Giese*

Departement Chemie der Universität Basel, St. Johannis-Ring 19, CH-4056 Basel

(24.V.96)

Two synthetic pathways towards 4'-C-acylthymidines are presented. These modified mononucleosides are precursors of the 2'-deoxyribonucleotide 4'-C-radical. They were converted into their corresponding 3'-O-[(2-cyanoethyl) *N,N*-diisopropylphosphoramidites] **3a-c** and incorporated in oligonucleotides by solid-phase synthesis. The structure of some modified nucleosides was revealed by X-ray crystal-structure analysis.


Introduction. – Antibiotics from the ene-diyne family like neocarzinostatin [1] and esperamycin [2] as well as metal complexes of bleomycin glycopeptides [3] induce the oxidative cleavage of DNA by generation of highly reactive DNA radicals. In a similar way, chemical nucleases and drugs can generate oxidative stress by damage of DNA *via* radicals [4]. The research in this area is focused on the development of new selective DNA cleavers and on the elucidation of the mechanism of action of these compounds. Whereas hydroxyl radicals react rather unselectively [5], several agents whose active center is bound to the minor groove preferentially abstract H-atoms from the 4'- and/or 5'-position of the deoxyribose [1–4]. Recently, we have demonstrated that 2'-deoxyribonucleotide 4'-C radicals can be generated selectively from selenide **1** or ketone **2** by photolysis [6]. These artificial oligonucleotides could be synthesized by solid-phase synthesis with suitably substituted mononucleotides. We have now worked out two different synthetic strategies towards 4'-C-acyl-2'-deoxyribonucleotides¹⁾ **3**.



¹⁾ For convenience, all compounds described in this work are named as 4'-C-substituted pentose derivatives although pentose is not always the parent monosaccharide.

Results and Discussion. – 1. *4'-C-Acylthymidines*¹⁾ **10a–d**. The first route towards the thymidylyl *4'-C* radical precursors **10a–d** starts from compound **5** [7] which was easily obtained from aldehyde **4** [8] (Scheme 1). After a protection/deprotection sequence using (*tert*-butyl)chlorodiphenylsilane in the presence of 1*H*-imidazole in DMF, followed by treatment with 80% AcOH in THF, compound **5** was converted to the bis-silylated derivative **6** in 74% yield. Swern oxidation [9] of **6** gave aldehyde **7** in 95% yield. The addition of MeMgCl (4 equiv.), EtMgCl (4.5 equiv.), or PhMgCl (6 equiv. and 0.2 equiv. CuI) in THF afforded the corresponding alkylated or arylated alcohols **8a–c** in 97, 63, and 79% yield, respectively. Oxidation of **8a–c** was achieved using the *Dess-Martin* reagent [10] in CH₂Cl₂ and afforded the protected *4'-C*-acetylthymidine **9a**, *4'-C*-propanoylthymidine **9b**, and *4'-C*-benzoylthymidine **9c** in 75, 78, and 99% yield, respectively. Treatment of **7** with *t*-BuLi (5 equiv.) in Et₂O (–78°, 2 min) gave only poor yields of the desired pivaloyl alcohol **8d**. The reaction was incomplete, and longer reaction times, higher temperatures, or higher *t*-BuLi concentrations did not improve the yield of **8d**, but led to by-products. The crude reaction mixture was directly oxidized under *Swern* conditions. Bis-silylated *4'-C*-pivaloylthymidine **9d** was obtained in 45% yield (from **7**) together with 19% of the starting aldehyde **7**. The last step of the synthesis consisted in the deprotection of the two silylated OH groups. Deprotection of **9a** (R = Me) and **9b** (R = Et) was achieved easily with tetrabutylammonium fluoride (Bu₄NF) in THF and gave **10a** in 84 and **10b** in 67% yield. Treatment of **9c** (R = Ph) with 2 equiv. of Bu₄NF in THF led to a complex mixture due to the instability of the free alcohol **10c** under basic conditions. Using 1 equiv. of Bu₄NF in THF at 0° led to mono-desilylation. Complete deprotection was then achieved by treatment with pyridinium poly(hydrogen fluoride) (Py·(HF)_n) in THF (25°) [11]. The deprotected thymidine **10c** was obtained in 18% yield. Attempts to deprotect **9d** (R = *t*-Bu) with Bu₄NF in THF were unsuccessful. However, reaction of **9d** with CsF (10 equiv.) in DMF (45°) afforded *4'-C*-pivaloylthymidine **10d** in 67% yield.


Scheme 1



TBDMS = (*t*-Bu)Me₂Si, TBDPS = (*t*-Bu)Ph₂Si, DMTr = 4,4'-dimethoxytrityl

The second pathway towards compounds **10** turned out to be more efficient (*Scheme 2*), but it is limited to 4'-*C*-acylthymidines which do not possess H-atoms in α -position to the carbonyl function. The strategy consists in generating the 4'-*C*-acyl function in the first steps starting from aldehyde **4**, then performing a 4'-*C*-(hydroxymethyl)ation. The *t*-Bu and Ph groups were introduced by 1,2-addition of organolithium [12] or organomagnesium [13] compounds to the 5'-aldehyde function of nucleoside **4** in the presence of CeCl₃. Alcohol **11b** (R = *t*-Bu) was obtained in 65% yield (1:1 diastereoisomer mixture) by treatment of **4** with *t*-BuLi (11 equiv.) and CeCl₃ (12 equiv.) in THF at -78°. Under similar conditions, nucleoside **4** was treated with PhMgBr (3 equiv.) and CeCl₃ (3 equiv., -5°) to give compound **11a** (R = Ph) in 82% yield as a 1:1 diastereoisomer mixture. Alternatively, **11a** could also be obtained (78% yield, isomer ratio 3:1) by treatment of **4** with PhMgBr (6 equiv.) in the presence of CuI (2 equiv.). *Svern* oxidation of the diastereoisomeric alcohols **11a, b** led to the corresponding ketones **12a** (85%) and **12b** (90%). Deprotection of the 3'-silyl ethers was performed using Bu₄NF in THF at 0° and yielded alcohols **13a** (89%) and **13b** (94%), respectively. The hydroxymethylation step was hoped to occur *via* an aldol reaction with formaldehyde under basic conditions. However, the reaction of both **13a** and **13b** with lithium diisopropylamide and gaseous formaldehyde failed. Attempts to perform the aldol reaction with aqueous formaldehyde in the presence of other bases (KOH, NaOH, LiOH, and Ca(OH)₂) led to complex reaction mixtures or decomposition. Acceptable results were obtained by using Ba(OH)₂. Treatment of alcohol **13b** (R = *t*-Bu) with Ba(OH)₂ (0.6 equiv.) in dioxane/H₂O 7:1 and addition of aqueous formaldehyde (9 equiv.) led to **10d** (65%) and **14b** (21%) as sole

Scheme 2



reaction products. When the phenyl ketone **13a** was treated with $\text{Ba}(\text{OH})_2$ (0.6 equiv.) in the presence of formaldehyde (5 equiv.) in dioxane/ H_2O 10:1, three products were formed. Two of them were the β -D-*erythro* and α -L-*threo* derivatives **10c** and **14a**, respectively, which were obtained in 73% yield as a 1:2.5 mixture, besides 22% of **15**. Separation of the isomers turned out to be very difficult. Attempts to separate **10c** and **14a** by flash chromatography (FC), MPLC, or reversed-phase MPLC failed, and separation by HPLC was of low efficiency. However, treatment of a mixture **10c/14a** with toluene-4-sulfonic acid in acetone led to the selective formation of the 3',5'-isopropylidene ketal **16** of the α -L-*threo* isomer which could be easily separated from **10c** by FC.

The β -D-*erythro* configuration of **10d** was assigned by an X-ray crystal-structure analysis (Fig. 1) and by comparison with the NMR data of the compound obtained by desilylation of **9d** (\rightarrow **10d**). The unit cell contained four molecules of **10d**, all with southern conformation phase angles [14] and 'anti' orientation of the base (pseudorotation phase angle $P_A = 168^\circ$, $P_B = 168^\circ$, $P_C = 200^\circ$, $P_D = 158^\circ$; ring conformations: 2T_3 , 2T_3 , 3E , and 2E ; glycosyl torsion angle $\chi_A = -129.1^\circ$, $\chi_B = -148.3^\circ$, $\chi_C = -171.8^\circ$, $\chi_D = -132.3^\circ$; C(4')–C(5') torsion angle $\gamma_A = 57.2^\circ$, $\gamma_B = 51.6^\circ$, $\gamma_C = 172.6^\circ$, $\gamma_D = 52.3^\circ$). These structures are very similar to the solid-state conformation of thymidine ($P = 188^\circ$; ${}^3T^2$; $\chi = -144^\circ$; $\gamma = 172.8^\circ$) [15]. The large $J(\text{H}-\text{C}(1'), \text{H}_{\text{pro-S}}-\text{C}(2'))$ of **10d** (10.1 Hz) in D_2O , as well as the undetectable small $J(\text{H}_{\text{pro-R}}-\text{C}(2'), \text{H}-\text{C}(3'))$ showed that the southern conformation is also highly preferred in solution [16]. The other acylated thymidines **10a–c** have also large $J(\text{H}-\text{C}(1'), \text{H}_{\text{pro-S}}-\text{C}(2'))$ (9.0, 9.1, and 9.6 Hz, resp.), thus strongly preferring the southern conformation, whereas thymidine exists as a 2:1 mixture of the southern and northern conformation [17]. The structure of the α -L-*threo* derivative **14b** was assigned by X-ray analysis (4E envelope, pseudorotation phase angle $P = 52^\circ$, Fig. 1).




Fig. 1. X-Ray crystal structures of compounds **10d** (molecule A) and **14b**. C–H Bonds are not represented.

The configuration of **10c** could be assigned by a ${}^1\text{H}$ -NOESY experiment as well as by comparison with the NMR data of the compound obtained after desilylation of **9c** (\rightarrow **10c**). NOE Experiments confirmed also the α -L-*threo* configuration of nucleoside **14a**. A medium NOE effect was observed between the H_{ortho} -atoms of the Ph group and H–C(6) of the thymine moiety. A much weaker interaction was also observed between H–C(1') and the hydroxymethyl group. To the third product, the structure of the

β -D-*threo* derivative **15** was assigned by an X-ray crystal-structure analysis (twisted ${}_4T^3$ conformation, pseudorotation phase angle $P = 48^\circ$, Fig. 2) as well as by NOE experiments.






Fig. 2. X-Ray crystal structure of compound **15**. C–H Bonds are not represented.

The formation of **15** can be explained by a ring opening/ring closing sequence (Scheme 3). Indeed, we could show that compound **10c** interconverts with the β -D-*threo* derivative **15** and the α -L-*threo* derivative **14a** under the basic reaction conditions ($\text{Ba}(\text{OH})_2$, 10% H_2O in dioxane). This *retro*-aldol reaction was only observed in the case of the 4'-C-benzoylnucleoside. It is favoured by a more effective stabilization of the intermediate anion by the benzoyl group compared with the pivaloyl function [18].



2. *Modified Oligonucleotides*¹⁾ **17a–c**. In order to become suitable building blocks for the solid-phase synthesis of modified oligonucleotides, **10a, c, d** were converted into the corresponding 3'-phosphoramidites **3a–c** (Scheme 4) [19]. Tritylation of the primary OH group was achieved by treatment of **10a, c, d** with 4,4'-dimethoxytrityl chloride (2 equiv.) in pyridine in the presence of a catalytic amount of 4-(dimethylamino)pyridine to give **17a–c** in 90, 80, and 85% yield, respectively. Phosphitylation [20] of the secondary OH group in **17a–c** with 2-cyanoethyl *N,N*-diisopropylphosphorochloridamidite (2.3 equiv.) and *N,N*-diisopropylethylamine in CH_2Cl_2 led to **3a** (92%), **3b** (76%), and **3c** (91%).

Scheme 4



The modified oligonucleotides **18a–c** were synthesized following the solid-phase phosphoramidite method [21] on an automated DNA synthesizer using **3a–c**, respectively, and commercially available 2'-deoxynucleoside [(2-cyanoethyl)phosphoramidites]. The coupling efficiency of the modified phosphoramidites **3a–c** was *ca.* 98%, as monitored by the release of the dimethoxytrityl cation during deprotection in the coupling cycle. The dimethoxytritylated oligonucleotides were removed from the solid support by treatment with concentrated ammonia at 55° for 8 h. After detritylation, desalting, and purification by HPLC, the relative molecular masses of the modified oligonucleotides **18a–c** were determined by MALDI-TOF mass spectrometry.

This work was supported from the Swiss National Science Foundation; P. E. thanks the *Amt für Ausbildungsbeiträge des Kantons Basel-Stadt* and the *Stipendienfonds der Sandoz AG* for financial support.

Experimental Part

General. All temp. quoted are uncorrected. All reagents are commercially available and used without further purification. The solvents were purified and dried according to standard procedures. The reactions were carried out in carefully dried apparatus and under Ar. Thin layer chromatography (TLC): precoated plates, silica gel F_{254} ,

Merck. Flash chromatography (FC): *Merck* silica gel 60 (0.040–0.063 mm). MPLC: *Büchi* chromatograph; *Macherey-Nagel* silica-gel column (*Polygosyl-60*, 15–25 μm). HPLC: *Kontron* chromatograph with UV detector (254 nm); anal. HPLC on *Merck RP-18 LiChrosorb* column and prep. HPLC on *Knauer RP-18* column. M.p.: *Büchi 530*; uncorrected. $[\alpha]_{\text{D}}^{25}$: *Perkin-Elmer-141* polarimeter (concentrations in g/ml). IR Spectra: *Perkin-Elmer-1600-FTIR* spectrophotometer (wavelengths in cm^{-1}). NMR Spectra: *Varian Gemini 300* (^1H at 300 MHz, ^{13}C at 75.5 MHz, ^{31}P at 121 MHz); chemical shifts δ in ppm rel. to internal SiMe_4 for ^1H ($= 0.0$ ppm), CDCl_3 for ^{13}C ($= 77.0$ ppm), CD_3OD for ^{13}C ($= 49.0$ ppm), and $\text{OP}(\text{O}^i\text{Pr})_3$ for ^{31}P ($= -18.0$ ppm), coupling constants J in Hz. NOE: irradiated H \rightarrow affected H; ++ = strong, + = medium, (+) = weak. MS: *VG 70-250* for fast-atom bombardment (FAB) ionization (3-nitrobenzyl alcohol (NBA) and NBA + KCl); *Vestec, Benchtop II* for matrix-assisted laser-desorption ionization (time-of-flight) (MALDI-TOF), matrix 2,4,6-trihydroxyacetophenone, laser wavelength 337 nm, acceleration voltage 15 kV. Microanalyses were performed at the Mikroanalytisches Labor, University of Basel.

3'-O-[(*tert*-Butyl)dimethylsilyl]-5'-O-[(*tert*-butyl)diphenylsilyl]-4'-C-(hydroxymethyl)thymidine (**6**). To a soln. of **5** (2.71 g, 3.93 mmol) and 1*H*-imidazole (0.80 g, 11.8 mmol) in DMF (7 ml), (*t*-Bu)Ph₂SiCl (1.11 ml, 4.33 mmol) was added at 25°. After stirring for 24 h at 25°, the mixture was poured onto H₂O (60 ml), extracted with CH₂Cl₂ (3 \times 80 ml), dried (MgSO₄), and evaporated. To the resulting yellow foam in THF (5 ml), 80% AcOH/H₂O (17 ml) was added. After stirring at 25° for 24 h, the mixture was cooled to 0°, neutralized with 25% aq. NH₃ soln. (20 ml), poured onto H₂O (80 ml), and extracted with CH₂Cl₂ (2 \times 50 ml). The combined org. phases were washed with sat. aq. NaHCO₃ soln. (100 ml), dried (MgSO₄), and evaporated. Flash chromatography (AcOEt/pentane 1:2) gave 1.82 g (74%) of **6**. Pale yellow foam. IR (KBr): 3433, 3200, 3071, 2955, 2930, 2892, 2857, 1690, 1472, 1428, 1259, 1114, 835, 778, 703. $^1\text{H-NMR}$ (CDCl₃): 0.07 (s, MeSi); 0.11 (s, MeSi); 0.91 (s, *t*-BuSi); 1.10 (s, *t*-BuSi); 1.62 (s, Me-C(5)); 2.27 (m, H_a-C(2'), OH); 2.36 (ddd, $J = 3.0, 6.0, 13.4$, H_b-C(2')); 3.63 (dd, $J = 8.7, 12.1$, 1 H, HOCH₂-C(4')); 3.77 (dd, $J = 5.0, 12.1$, 1 H, HOCH₂-C(4')); 3.80 (d, $J = 11.1$, H_a-C(5')); 3.88 (d, $J = 11.1$, H_b-C(5')); 4.67 (dd, $J = 3.0, 6.4$, H-C(3')); 6.41 (dd, $J = 6.0, 7.8$, H-C(1')); 7.42 (m, arom. H, H-C(6)); 7.66 (m, arom. H); 9.15 (s, NH). $^{13}\text{C-NMR}$ (CDCl₃): -5.2 (MeSi); -5.0 (MeSi); 12.0 (Me-C(5)); 17.9 (Me₃CSi); 19.3 (Me₃CSi); 25.6 (Me₃CSi); 27.0 (Me₃CSi); 41.8 (C(2')); 63.6 (HOCH₂-C(4')); 65.6 (C(5')); 73.6 (C(3')); 84.2 (C(1')); 89.0 (C(4')); 111.1 (C(5)); 127.9–135.5 (arom. C, C(6)); 150.3 (C(2)); 163.8 (C(4)). FAB-MS: 625 (2, [M + 1]⁺). Anal. calc. for C₃₃H₄₈N₂O₆Si₂ (624.93): C 63.43, H 7.74, N 4.48; found: C 63.31, H 7.83, N 4.49.

3'-O-[(*tert*-Butyl)dimethylsilyl]-5'-O-[(*tert*-butyl)diphenylsilyl]-4'-C-formylthymidine (**7**). To a soln. of trichloroacetic anhydride (0.40 ml, 2.14 mmol) in CH₂Cl₂ (6 ml), DMSO (0.20 ml, 2.98 mol) was added at -70°. After stirring for 15 min at -70°, a soln. of **6** (0.92 g, 1.46 mmol) in CH₂Cl₂ (2 ml) was added. After stirring for another 30 min at -70°, Et₃N (0.99 ml, 7.01 mmol) was added and the mixture warmed to 25° within 30 min. The mixture was poured onto H₂O (60 ml), extracted with CH₂Cl₂ (3 \times 40 ml), dried (MgSO₄), and evaporated. Flash chromatography (AcOEt/pentane 1:1) gave 0.86 g (95%) of **7**. Pale yellow foam. IR (NaCl dissolved in CH₂Cl₂): 3187, 3071, 2931, 2858, 1694, 1472, 1428, 1363, 1281, 1263, 1114, 829. $^1\text{H-NMR}$ (CDCl₃): 0.02 (s, MeSi); 0.04 (s, MeSi); 0.85 (s, *t*-BuSi); 1.10 (s, *t*-BuSi); 1.64 (d, $J = 1.2$, Me-C(5)); 2.31 (m, H-C(2')); 3.91 (d, $J = 11.5$, H_a-C(5')); 4.11 (d, $J = 11.5$, H_b-C(5')); 4.66 (m, H-C(3')); 6.70 (dd, $J = 6.3, 8.2$, H-C(1')); 7.43 (m, arom. H); 7.53 (d, $J = 1.2$, H-C(6)); 7.64 (m, arom. H); 9.09 (s, NH); 9.53 (s, C(O)H). $^{13}\text{C-NMR}$ (CDCl₃): -5.4 (MeSi); -4.9 (MeSi); 12.0 (Me-C(5)); 17.9 (Me₃CSi); 19.3 (Me₃CSi); 25.5 (Me₃CSi); 41.3 (C(2')); 64.5 (C(5')); 76.2 (C(3')); 86.1 (C(1')); 92.8 (C(4')); 111.5 (C(5)); 127.9–135.5 (arom. C, C(6)); 150.3 (C(2)); 163.7 (C(4)); 200.2 (CHO). FAB-MS: 623 (2, [M + 1]⁺). Anal. calc. for C₃₃H₄₆N₂O₆Si₂ (622.91): C 63.63, H 7.44, N 4.50; found: C 63.28, H 7.40, N 4.39.

3'-O-[(*tert*-Butyl)dimethylsilyl]-5'-O-[(*tert*-butyl)diphenylsilyl]-4'-C-(1-hydroxyethyl)thymidine (**8a**). To a soln. of **7** (0.60 g, 0.96 mmol) in THF (10 ml), 3*M* MeMgCl in THF (1.20 ml, 3.60 mmol) was added at 0°. After stirring for 2 h at 0°, a sat. aq. NH₄Cl soln. (20 ml) was added and extracted with CH₂Cl₂ (3 \times 100 ml). The combined org. phases were washed with H₂O (100 ml), dried (MgSO₄), and evaporated: 0.60 g (97%) of **8a** as a 3:1 diastereoisomer mixture which was used in the next step without further purification. IR (KBr): 3448, 3071, 2954, 2931, 1744, 1686, 1472, 1252, 1228, 703. $^1\text{H-NMR}$ (CDCl₃): major diastereoisomer: 0.13 (s, MeSi); 0.17 (s, MeSi); 0.93 (s, *t*-BuSi); 1.12 (s, *t*-BuSi); 1.17 (d, $J = 6.7$, MeCH(OH)); 1.54 (d, $J = 1.1$, Me-C(5)); 2.35 (m, H-C(2')); 2.87 (s, OH); 4.00 (d, $J = 11.5$, H_a-C(5')); 4.10 (d, $J = 11.5$, H_b-C(5')); 4.14 (d, $J = 6.7$, MeCH(OH)); 4.84 (dd, $J = 3.8, 6.7$, H-C(3')); 6.33 (t, $J = 7.2$, H-C(1')); 7.44 (m, arom. H, H-C(6)); 7.66 (m, arom. H); 8.52 (s, NH); minor diastereoisomer: 0.11 (s, MeSi); 0.15 (s, MeSi); 0.93 (s, *t*-BuSi); 1.00 (s, *t*-BuSi); 1.25 (d, $J = 4.7$, MeCH(OH)); 1.61 (d, $J = 1.2$, Me-C(5)); 2.36 (m, H-C(2')); 3.38 (s, OH); 3.60 (d, $J = 11.2$, H_a-C(5')); 3.80 (d, $J = 11.2$, H_b-C(5')); 3.84 (d, $J = 4.7$, MeCH(OH)); 4.84 (dd, $J = 2.4, 6.9$, H-C(3')); 6.49 (dd, $J = 6.0, 8.2$, H-C(1')); 7.44 (m, arom. H, H-C(6)); 7.66 (m, arom. H); 8.52 (s, NH). $^{13}\text{C-NMR}$ (CDCl₃): major diastereoisomer: -5.1 (MeSi); -4.3 (MeSi); 12.0 (Me-C(5)); 17.1 (MeCH(OH)); 17.9 (Me₃CSi); 19.5 (Me₃CSi); 25.7 (Me₃CSi); 27.2 (Me₃CSi); 41.6 (C(2')); 63.6 (C(5')); 68.2 (MeCH(OH)); 73.6 (C(3')); 83.6 (C(1')); 89.3 (C(4'));

111.3 (C(5)); 128.0–135.5 (arom. C, C(6)); 150.3 (C(2)); 163.7 (C(4)); minor diastereoisomer: –5.1 (MeSi); –4.5 (MeSi); 12.1 (Me–C(5)); 16.8 (MeCH(OH)); 18.8 (Me₃CSi); 19.4 (Me₃CSi); 27.1 (Me₃CSi); 27.2 (Me₃CSi); 42.7 (C(2')); 65.1 (C(5')); 69.0 (MeCH(OH)); 74.5 (C(3')); 84.6 (C(1')); 90.8 (C(4')); 111.1 (C(5)); 128.0–135.6 (arom. C, C(6)); 150.2 (C(2)); 163.9 (C(4)). FAB-MS: 639 (1, [M + 1]⁺). Anal. calc. for C₃₄H₅₀N₂O₆Si₂ (638.96): C 63.91, H 7.89, N 4.38; found: C 63.74, H 8.04, N 4.23.

3'-O-[(*tert*-Butyl)dimethylsilyl]-5'-O-[(*tert*-butyl)diphenylsilyl]-4'-C-(1-hydroxypropyl)thymidine (**8b**). To a soln. of **7** (62 mg, 0.10 mmol) in THF (2 ml), 1.5M EtMgBr (0.3 ml, 0.45 mmol) in Et₂O was added at –78°. After stirring for 1.5 h at –78°, a sat. aq. NH₄Cl soln. (20 ml) was added and the mixture extracted with CH₂Cl₂ (50, 20, and 20 ml). The combined org. phases were washed with H₂O (20 ml), dried (MgSO₄), and evaporated. FC (pentane/acetone 3:1) yielded 41 mg (63%) of **8b** (major diastereoisomer). The minor diastereoisomer could not be isolated as a pure compound. Additionally 8 mg (13%) of the reduction product **6** were obtained. Major diastereoisomer: IR (KBr): 3323, 3233, 3074, 2954, 2931, 2893, 2857, 1718, 1702, 1683, 1472, 1428, 1273, 1205, 1086, 1036, 832, 778, 710, 700, 505. ¹H-NMR (CDCl₃): 0.12 (s, MeSi); 0.16 (s, MeSi); 0.93 (s, *t*-BuSi); 0.96 (t, *J* = 7.2, Me); 1.10 (s, *t*-BuSi); 1.20 (m, 1 H, CH₂CH(OH)); 1.54 (d, *J* = 1.2, Me–C(5)); 1.66 (m, 1H, CH₂CH(OH)); 2.30 (m, H_a–C(2')); 2.38 (ddd, *J* = 3.9, 6.3, 13.4, H_b–C(2')); 2.80 (dd, ⁴*J* = 1.2, *J* = 4.1, OH); 3.78 (ddd, *J* = 2.0, 4.1, 10.8, CH₂CH(OH)); 3.96 (d, *J* = 11.4, H_a–C(5')); 4.10 (d, *J* = 11.4, H_b–C(5')); 4.81 (dd, *J* = 3.9, 6.3, H–C(3')); 6.31 (dd, *J* = 6.3, 7.3, H–C(1')); 7.42 (m, arom. H, H–C(6)); 7.65 (m, arom. H); 8.96 (s, NH); minor diastereoisomer: 0.09 (s, MeSi); 0.13 (s, MeSi); 0.91 (s, *t*-BuSi); 0.94 (t, *J* = 7.2, Me); 1.09 (s, *t*-BuSi); 1.40 (m, CH₂CH(OH)); 1.57 (s, Me–C(5)); 2.30 (m, H–C(2')); 3.03 (dd, *J* = 1.5, 2.9, OH); 3.67 (d, *J* = 11.0, H_a–C(5')); 3.85 (d, *J* = 11.2, H_b–C(5')); 3.95 (m, CH₂CH(OH)); 4.75 (dd, *J* = 2.7, 6.8, H–C(3')); 6.45 (dd, *J* = 6.1, 8.1, H–C(1')); 7.40 (m, arom. H, H–C(6)); 7.64 (m, arom. H); 8.46 (s, NH). ¹³C-NMR (CDCl₃): major diastereoisomer: –5.1 (MeSi); –4.4 (MeSi); 11.3 (MeCH₂); 11.9 (Me–C(5)); 17.8 (Me₃CSi); 19.4 (Me₃CSi); 23.7 (CH₂CH(OH)); 25.7 (Me₃CSi); 27.1 (Me₃CSi); 41.5 (C(2')); 63.6 (C(5')); 73.5, 73.8 (CH₂CH(OH), C(3')); 83.4 (C(1')); 89.4 (C(4')); 111.3 (C(5)); 127.9, 128.0 (C_m); 130.0, 130.2 (C_p); 132.3, 132.9 (C_{ipso}); 135.1 (C(6)); 135.2, 135.4 (C_a); 150.3 (C(2)); 163.7 (C(4)). FAB-MS: 653 (3, [M + 1]⁺).

3'-O-[(*tert*-Butyl)dimethylsilyl]-5'-O-[(*tert*-butyl)diphenylsilyl]-4'-C-[hydroxy(phenyl)methyl]thymidine (**8c**). CuI (0.04 g, 0.20 mmol) was suspended in a soln. of **7** (0.70 g, 1.12 mmol) in THF (50 ml) at –5°, and 1M PhMgBr (6.00 ml, 6.00 mmol) was added slowly. The mixture was stirred for 2 h at –5° and for 1 h at 0°. Sat. aq. NH₄Cl soln. (20 ml) was added and the aq. phase extracted with Et₂O (7 × 50 ml). The org. phase was dried (MgSO₄) and evaporated. FC (AcOEt/pentane 1:2) yielded 0.62 g (79%) of **8c**. Colourless foam of one single diastereoisomer. ¹H-NMR (CDCl₃): 0.17 (s, MeSi); 0.18 (s, MeSi); 0.97 (s, *t*-BuSi); 1.07 (s, *t*-BuSi); 1.57 (d, *J* = 1.2, Me–C(5)); 2.15 (m, H_a–C(2')); 2.34 (m, H_b–C(2')); 3.26 (d, *J* = 11.1, H_a–C(5')); 3.46 (d, *J* = 11.1, H_b–C(5')); 4.04 (d, *J* = 2.5, OH); 4.82 (d, *J* = 2.9, H–C(3')); 4.94 (dd, *J* = 2.5, 7.5, PhCH(OH)); 6.59 (dd, *J* = 6.3, 7.8, H–C(1')); 7.40 (m, Ph, H–C(6)); 8.6 (s, NH). ¹³C-NMR (CDCl₃): –4.7 (MeSi); –4.2 (Me–C(5)); 18.2 (Me₃CSi); 19.9 (Me₃CSi); 26.0 (Me₃CSi); 27.4 (Me₃CSi); 42.5 (C(2')); 66.4 (C(5')); 75.6 (C(5')); 75.9 (C(3')); 85.5 (C(1')); 90.5 (C(4')); 111.3 (C(5)); 128.2–139.0 (C(6), arom. C); 150.2 (C(2)); 163.6 (C(4)). FAB-MS: 701 (5, [M + 1]⁺). Anal. calc. for C₃₉H₅₂N₂O₅Si₂ (700.01): C 66.82, H 7.48, N 4.00; found: C 66.82, H 7.47, N 3.84.

4'-C-Acetyl-3'-O-[(*tert*-butyl)dimethylsilyl]-5'-O-[(*tert*-butyl)diphenylsilyl]thymidine (**9a**). To a soln. of 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1*H*)-one (0.43 g, 1.02 mmol) in CH₂Cl₂ (7 ml), a soln. of **8a** (0.32 g, 0.51 mmol) in CH₂Cl₂ (3 ml) was added at 25°. After stirring for 1 h, the mixture was poured in sat. aq. NaHCO₃ soln./sat. aq. Na₂S₂O₃ soln. 1:1 (50 ml, v/v), extracted with Et₂O (3 × 100 ml), dried (MgSO₄), and evaporated. FC (AcOEt/pentane 1:3) gave 0.24 g (75%) of **9a**. Colourless foam. ¹H-NMR (CDCl₃): 0.01 (s, MeSi); 0.04 (s, MeSi); 0.86 (s, *t*-BuSi); 1.10 (s, *t*-BuSi); 1.59 (s, Me–C(5)); 2.28 (m, H–C(2'), MeCO); 3.95 (d, *J* = 11.3, H_a–C(5')); 4.14 (d, *J* = 11.2, H_b–C(5')); 4.50 (m, H–C(3')); 6.66 (dd, *J* = 6.3, 8.7, H–C(1')); 7.42 (m, arom. H); 7.61 (m, H–C(6), arom. H); 8.98 (s, NH). ¹³C-NMR (CDCl₃): –5.4 (MeSi); –5.1 (MeSi); 12.0 (Me–C(5)); 17.9 (Me₃CSi); 19.5 (Me₃CSi); 25.7 (Me₃CSi); 27.1 (Me₃CSi); 28.7 (MeCO); 41.6 (C(2')); 66.7 (C(5')); 76.2 (C(3')); 86.3 (C(1')); 96.3 (C(4')); 111.4 (C(5)); 128.0–135.5 (arom. C, C(6)); 150.4 (C(2)); 163.8 (C(4)); 208.8 (MeCO). FAB-MS: 637 (3, [M + 1]⁺). Anal. calc. for C₃₄H₄₈N₂O₆Si₂ (636.94): C 64.11, H 7.60, N 4.40; found: C 64.12, H 7.78, N 4.24.

3'-O-[(*tert*-Butyl)dimethylsilyl]-5'-O-[(*tert*-butyl)diphenylsilyl]-4'-C-propanoylthymidine (**9b**). A soln. of 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1*H*)-one (156 mg, 2.12 mmol) and **8b** (major diastereoisomer; 96 mg, 0.15 mmol) in CH₂Cl₂ (5 ml) at 25° was stirred for 1 h. Then the mixture was poured in sat. aq. NaHCO₃ soln. (10 ml) and sat. aq. Na₂S₂O₃ soln. (10 ml), extracted with *t*-BuOMe (3 × 20 ml), dried (MgSO₄), and evaporated. FC (acetone/pentane 1:3) gave 75 mg (78%) of **9b**. Colourless foam. IR (KBr): 3414, 3192, 3072, 2955, 2931, 2886, 2858, 1718, 1700, 1472, 1428, 1279, 1254, 1114, 1076, 1035, 958, 834, 779, 703, 505. ¹H-NMR (CDCl₃): –0.03 (s, MeSi); 0.03 (MeSi); 0.84 (s, *t*-BuSi); 0.96 (t, *J* = 7.1, MeCH₂O); 1.10 (s, *t*-BuSi); 1.59 (s, Me–C(5)); 2.28 (m, H–C(2')); 2.58 (qd, *J* = 7.1, 19.4, 1 H, MeCH₂CO); 2.82 (qd, *J* = 7.1, 19.4, 1 H, MeCH₂CO);

3.94 (*d*, *J* = 11.2, H_a-C(5')); 4.11 (*d*, *J* = 11.2, H_b-C(5')); 4.49 (*d*, *J* = 3.6, H-C(3')); 6.65 (*dd*, *J* = 5.7, 8.9, H-C(1')); 7.42 (*m*, arom. H); 7.63 (*m*, H-C(6), arom. H); 9.05 (*s*, NH). ¹³C-NMR (CDCl₃): -5.3 (MeSi); -5.2 (MeSi); 6.6 (MeCH₂CO); 12.0 (Me-C(5)); 17.9 (Me₃CSi); 19.4 (Me₃CSi); 25.6 (Me₃CSi); 27.0 (Me₃CSi); 33.6 (MeCH₂CO); 41.6 (C(2')); 67.0 (C(5')); 76.0 (C(3')); 86.2 (C(1')); 96.5 (C(4')); 111.3 (C(5)); 128.0, 128.1 (C_m); 130.1, 130.3 (C_p); 132.0, 132.6 (C_{qso}); 135.26 (C(6)); 135.31, 135.5 (C_a); 150.3 (C(2)); 163.8 (C(4)); 210.8 (MeCH₂CO). FAB-MS: 651 (3, [M + 1]⁺). Anal. calc. for C₃₅H₅₀N₂O₆Si₂ (650.97): C 64.58, H 7.74, N 4.30; found: C 64.46, H 7.61, N 4.11.

4'-C-Benzoyl-3'-O-[(tert-butyl)dimethylsilyl]-5'-O-[(tert-butyl)diphenylsilyl]thymidine (**9c**). To a soln. of 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (0.43 g, 1.02 mmol) in CH₂Cl₂ (10 ml), a soln. of **8c** (0.46 g, 0.66 mmol) in CH₂Cl₂ (5 ml) was added at 25°. After stirring for 1 h, the mixture was poured in sat. aq. NaHCO₃ soln./sat. aq. Na₂S₂O₃ soln. 1:1 (60 ml; *v/v*), extracted with Et₂O (3 × 100 ml), dried (MgSO₄), and evaporated: 0.45 g (99%) of **9c**. Colourless foam which was used in the next step without further purification. ¹H-NMR (CDCl₃): -0.06 (*s*, MeSi); 0.06 (*s*, MeSi); 0.74 (*s*, *t*-BuSi); 1.61 (*d*, *J* = 1.2, Me-C(5)); 2.33 (*m*, H_a-C(2')); 2.40 (*m*, H_b-C(2')); 4.21 (*d*, *J* = 11.1, H_a-C(5')); 4.22 (*d*, *J* = 11.1, H_b-C(5')); 4.64 (*d*, *J* = 4.8, H-C(3')); 6.64 (*dd*, *J* = 6.3, 9.3, H-C(1')); 7.59 (*m*, H-C(6), arom. H); 8.16 (*s*, NH). ¹³C-NMR (CDCl₃): -5.2 (MeSi); -4.9 (MeSi); 12.0 (Me-C(5)); 17.9 (Me₃CSi); 19.4 (Me₃CSi); 25.6 (Me₃CSi); 27.0 (Me₃CSi); 41.7 (C(2')); 68.4 (C(5')); 77.2 (C(3')); 86.5 (C(1')); 98.5 (C(4')); 110.9 (C(5)); 127.9-135.6 (C(6), arom. C); 150.0 (C(2)); 163.4 (C(4)); 201.4 (C(5')). FAB-MS: 699 (2.6, [M + 1]⁺).

3'-O-[(tert-Butyl)dimethylsilyl]-5'-O-[(tert-butyl)diphenylsilyl]-4'-C-(1,1-dimethylpropanoyl)thymidine (**9d**). To a soln. of **7** (4.00 g, 6.42 mmol) in Et₂O (180 ml) at -78°, 1.6M *t*-BuLi (20.0 ml, 32.0 mmol) in pentane was added. After stirring for 2 min, sat. aq. NH₄Cl soln. (12 ml) was added and the mixture warmed to 25°. The mixture was poured onto H₂O (200 ml), extracted with CH₂Cl₂ (4 × 400 ml), dried (MgSO₄), and evaporated to yield a colourless foam. A soln. of the crude product in CH₂Cl₂ (10 ml) was added to a soln. of trichloroacetic anhydride (2.10 ml, 10.8 mmol) and DMSO (1.00 ml, 15.1 mmol) in CH₂Cl₂ (30 ml) at -70°. After stirring for 30 min at -70°, Et₃N (5.20 ml, 35.9 mmol) was added and stirring continued for additional 5 min before warming up to 25°. The mixture was poured onto H₂O, extracted with CH₂Cl₂ (3 × 50 ml), dried (MgSO₄), and evaporated. FC (AcOEt/pentane 1:3) gave 1.96 g (45%) of **9d** and 0.82 g (19%) of **7**. ¹H-NMR (CDCl₃): 0.01 (*s*, MeSi); 0.07 (*s*, MeSi); 0.87 (*s*, *t*-BuSi); 1.10 (*s*, *t*-BuSi); 1.20 (*s*, *t*-BuC); 1.56 (*s*, Me-C(5)); 2.26 (*dd*, *J* = 5.2, 12.4, H_a-C(2')); 2.35 (*ddd*, *J* = 4.2, 9.8, 12.4, H_b-C(2')); 3.97 (*d*, *J* = 11.1, H_a-C(5')); 4.03 (*d*, *J* = 11.1, H_b-C(5')); 4.50 (*d*, *J* = 4.2, H-C(3')); 6.64 (*dd*, *J* = 5.2, 9.8, H-C(1')); 7.44 (*m*, arom. H); 7.63 (*m*, H-C(6), arom. H); 8.23 (*s*, NH). ¹³C-NMR (CDCl₃): -5.2 (MeSi); -5.0 (MeSi); 11.9 (Me-C(5)); 18.0 (Me₃CSi); 19.5 (Me₃CSi); 25.8 (Me₃CSi); 25.9 (Me₃CSi); 27.2 (Me₃C); 41.2 (C(2')); 45.2 (Me₃C); 70.0 (C(5')); 77.2 (C(3')); 85.8 (C(1')); 99.6 (C(4')); 111.2 (C(5)); 128.0-135.6 (arom. C, C(6)); 150.1 (C(2)); 163.4 (C(4)); 213.4 (*t*-BuCO). FAB-MS: 718 (2, [M + 1]⁺).

4'-C-Acetylthymidine (**10a**). To a soln. of **9a** (0.48 g, 0.75 mmol) in THF (15 ml), 1M Bu₄NF (1.92 ml, 1.92 mmol) was added at 25° and stirred for 3 h. Silica gel (2 g) was added and the solvent evaporated. FC (AcOEt/MeCN 4:1) gave 0.18 g (84%) of **10a**. Colourless foam. IR (KBr): 3420, 3062, 1701, 1474, 1413, 1357, 1275, 1102, 1054, 1010. ¹H-NMR (CD₃OD): 1.88 (*d*, *J* = 1.0, Me-C(5)); 2.25 (*s*, MeCO); 2.30 (*m*, H-C(2')); 3.86 (*s*, H-C(5')); 4.46 (*m*, H-C(3')); 6.58 (*dd*, *J* = 5.9, 9.0, H-C(1')); 7.86 (*q*, *J* = 1.0, H-C(6)). ¹³C-NMR (CD₃OD): 12.5 (Me-C(5)); 28.9 (MeCO); 41.3 (C(2')); 65.5 (C(5')); 75.5 (C(3')); 87.8 (C(1')); 97.8 (C(4')); 111.8 (C(5)); 138.2 (C(6)); 152.4 (C(2)); 166.4 (C(4)); 211.7 (MeCO). FAB-MS: 285 (46, [M + 1]⁺). Anal. calc. for C₁₂H₁₆N₂O₂ · 0.8 H₂O (298.69): C 48.21, H 5.95, N 9.48; found: C 48.18, H 5.90, N 9.12.

4'-C-Propanoylthymidine (**10b**). To a soln. of **9b** (0.23 g, 0.35 mmol) in THF (15 ml), 1M Bu₄NF (0.9 ml, 0.9 mmol) was added at 25° and stirred for 5 h. Silica gel (3 g) was added and the solvent evaporated. FC (AcOEt/MeCN 4:1), removal of the solvent *in vacuo*, dissolution in H₂O and lyophilization gave 72 mg (67%) of **10b**. Colourless foam. IR (KBr): 3412, 3063, 2979, 2939, 1700, 1474, 1406, 1376, 1115, 1047, 962, 779, 572. ¹H-NMR (CD₃OD): 0.99 (*t*, *J* = 7.2, MeCH₂CO); 1.89 (*d*, *J* = 1.2, Me-C(5)); 2.30 (*m*, H-C(2')); 2.68 (*m*, MeCH₂CO); 3.84 (*d*, *J* = 11.7, H_a-C(5')); 3.89 (*d*, *J* = 11.7, H_b-C(5')); 4.46 (*m*, H-C(3')); 6.57 (*dd*, *J* = 5.7, 8.9, H-C(1')); 7.85 (*q*, *J* = 1.2, H-C(6)). ¹³C-NMR (CD₃OD): 7.3 (MeCH₂CO); 12.5 (Me-C(5)); 34.8 (MeCH₂CO); 41.2 (C(2')); 65.6 (C(5')); 75.5 (C(3')); 87.8 (C(1')); 98.0 (C(4')); 112.0 (C(5)); 138.2 (C(6)); 152.5 (C(2)); 166.6 (C(4)); 214.3 (MeCH₂CO). FAB-MS: 299 (31, [M + 1]⁺). Anal. calc. for C₁₃H₁₈N₂O₆ · 0.35 H₂O (304.61): C 51.26, H 6.19, N 9.20, O 33.35; found: C 51.13, H 6.24, N 9.05, O 33.05.

4'-C-Benzoylthymidine (**10c**). To a soln. of **9c** (6.5 mg, 0.01 mmol) in THF (2 ml), 1M Bu₄NF (0.01 ml, 0.01 mmol) was added at 0°. After stirring for 1 h at 0°, the mixture was directly chromatographed (CH₂Cl₂/MeOH 16:1) to remove Bu₄NF. After evaporation *in vacuo*, the residue was dissolved in THF (2 ml), and pyridinium poly(hydrogen fluoride) (0.07 ml, 70% HF) was added at 25°. After stirring for 2 d, the mixture was poured onto sat. aq. NaHCO₃ soln. (25 ml), extracted with AcOEt (4 × 50 ml), dried (MgSO₄), and evaporated. FC (CH₂Cl₂/MeOH 16:1) gave 0.6 mg (18%) of **10c**. For data, see below.

4'-C-(1,1-Dimethylpropanoyl)thymidine (10d). A suspension of **9d** (0.17 g, 0.25 mmol) and CsF (0.38 g, 2.52 mmol) in DMF (1.5 ml) was stirred for 15 h at 45°. The solvent was evaporated, the residue suspended in AcOEt (10 ml) and washed with H₂O (10 ml), and the phase extracted with AcOEt (5 × 10 ml). The combined org. phase was dried (MgSO₄) and evaporated. FC (AcOEt/pentane 4:1) gave 0.06 g (67%) of **10d**. Colourless solid. M.p. 192–194°. $[\alpha]_D^{25} = +11.3$ ($c = 0.011$, MeOH). IR (KBr): 3440, 3060, 2970, 1690, 1470, 1270, 1100, 1050. ¹H-NMR (CD₃OD): 1.21 (*s*, *t*-BuC); 1.89 (*d*, $J = 1.2$, Me–C(5)); 2.19 (*dd*, $J = 5.2$, 13.0, H_a–C(2')); 2.37 (*ddd*, $J = 4.8$, 10.1, 13.0, H_b–C(2')); 3.78 (*d*, $J = 11.5$, H_a–C(5')); 3.83 (*d*, $J = 11.5$, H_b–C(5')); 4.46 (*d*, $J = 4.8$, H–C(3')); 6.63 (*dd*, $J = 5.2$, 10.1, H–C(1')); 7.99 (*q*, $J = 1.2$, H–C(6)). ¹³C-NMR (CD₃OD): 12.5 (*Me*–C(5)); 26.5 (*Me*₃C); 40.6 (C(2')); 46.1 (*Me*₃C); 68.4 (C(5')); 76.9 (C(3')); 87.3 (C(1')); 101.3 (C(4')); 111.9 (C(5)); 138.3 (C(6)); 152.6 (C(2)); 166.4 (C(4)); 216.9 (*t*-BuCO). FAB-MS: 327 (30, $[M + 1]^+$). Anal. calc. for C₁₅H₂₂N₂O₆·0.2 H₂O (329.95): C 54.55, H 6.80, N 8.49; found: C 54.59, H 7.18, N 8.44.

3'-O-[(tert-Butyl)dimethylsilyl]-5'-C-phenylthymidine (11a). a) CeCl₃·7 H₂O (0.63 g, 1.70 mmol) was heated under stirring at 140° *in vacuo* (0.1 Torr) for 10 h (100-ml three-necked flask). After cooling to 0°, THF (10 ml) was added, and stirring was continued for 15 h. The mixture was then agitated at –5° for 10 min, and a soln. of aldehyde **4** (0.20 g, 0.56 mmol) in THF (10 ml) was added. Stirring at –5° was continued for 15 min. To the resulting suspension, 1*M* PhMgBr in THF (1.7 ml, 1.70 mmol) was added slowly (white → yellow). After 2 h at –5° and 1 h at 0°, the mixture was quenched with sat. aq. NH₄Cl soln. (25 ml), the resulting pale yellow suspension poured onto H₂O (100 ml), extracted with Et₂O (3 × 100 ml), dried (MgSO₄), and evaporated. FC (CH₂Cl₂/EtOH 20:1) gave 0.20 g (82%) of **11a** as a 1:1 diastereoisomer mixture. Colourless foam.

b) To a soln. of **4** (2.00 g, 5.60 mmol) in THF (80 ml) at –5°, CuI (0.21 g, 1.10 mmol) was added, the mixture agitated for 10 min, and 1*M* PhMgBr in THF (3.40 ml, 3.40 mmol) added. After stirring for 2 h at –5°, the mixture was hydrolyzed with sat. NH₄Cl soln. (100 ml) and extracted with Et₂O (8 × 100 ml), dried (MgSO₄), and evaporated. FC (CH₂Cl₂/EtOH 20:1) gave 1.90 g (78%) of **11a** as a 2.5:1 diastereoisomer mixture. Colourless foam. IR (KBr): 3397, 3211, 3063, 2929, 2856, 1695, 1472, 1276, 1105, 1072, 836, 777, 702. ¹H-NMR (CDCl₃): major diastereoisomer: 0.02 (*s*, MeSi); 0.86 (*s*, *t*-BuSi); 1.92 (*s*, Me–C(5)); 2.17 (*ddd*, $J = 2.8$, 5.1, 10.3, H_a–C(2')); 2.35 (*m*, H_b–C(2')); 3.43 (*d*, $J = 4.9$, OH–C(5')); 4.08 (*dd*, $J = 3.3$, 3.5, H–C(4')); 4.52 (*m*, H–C(3')); 4.81 (*dd*, $J = 3.5$, 4.9, H–C(5')); 6.11 (*dd*, $J = 5.1$, 8.0, H–C(1')); 7.28–7.52 (*m*, arom. H, H–C(6)); 9.24 (*s*, NH); minor diastereoisomer: 0.02 (*s*, MeSi); 0.72 (*s*, *t*-BuSi); 1.93 (*s*, Me–C(5)); 2.04 (*m*, H_a–C(2')); 2.42 (*m*, H_b–C(2')); 4.03 (*d*, $J = 2.2$, OH–C(5')); 4.12 (*dd*, $J = 1.3$, 2.3, H–C(4')); 4.44 (*m*, H–C(3')); 5.03 (*dd*, $J = 1.3$, 2.3, H–C(5')); 6.16 (*dd*, $J = 5.5$, 9.6, H–C(1')); 7.31–7.67 (*m*, arom. H, H–C(6)); 9.00 (*s*, NH). ¹³C-NMR (CDCl₃): major diastereoisomer: –4.7 (MeSi); –4.6 (MeSi); 12.5 (*Me*–C(5)); 17.9 (Me₃CSi); 25.8 (Me₃CSi); 39.9 (C(2')); 70.6 (C(5')); 72.6 (C(3')); 87.6 (C(1')); 90.9 (C(4')); 110.8 (C(5)); 125.9–128.8 (arom. C); 137.3 (C(6)); 150.3 (C(2)); 163.8 (C(4)); minor diastereoisomer: –4.9 (MeSi); –4.8 (MeSi); 12.4 (*Me*–C(5)); 17.9 (Me₃CSi); 25.7 (Me₃CSi); 40.0 (C(2')); 70.4 (C(5')); 73.2 (C(3')); 87.5 (C(1')); 90.4 (C(4')); 111.0 (C(5)); 125.9–128.8 (arom. C); 137.2 (C(6)); 150.3 (C(2)); 164.4 (C(4)). FAB-MS: 433 (11, $[M + 1]^+$). Anal. calc. for C₂₂H₃₂N₂O₅Si (432.60): C 61.08, H 7.46, N 6.48; found: C 60.76, H 7.70, N 6.48.

1-{3'-O-[(tert-Butyl)dimethylsilyl]-2',6',7'-trideoxy-6',6'-di-C-methyl-β-D-ribo-α-L-lyxo-heptofuranosyl]-thymine (11b). CeCl₃·7 H₂O (63.2 g, 170 mmol) was heated under stirring at 140° *in vacuo* (0.1 Torr) for 7 h (1-l three-necked flask). After cooling to 0°, THF (440 ml) was added and stirring continued for 15 h. The resulting suspension was cooled to –78° and 1.6*M* *t*-BuLi in pentane (99 ml, 158 mmol) added slowly (white → orange). After stirring at –78° for 1 h, a soln. of aldehyde **4** (5.02 g, 14.1 mmol) in THF (44 ml) was added slowly and stirring at –78° continued for 15 h. The mixture was quenched at –78° with 80% AcOH/H₂O (22 ml). The resulting pale yellow suspension was poured onto H₂O (500 ml) and extracted with AcOEt (3 × 600 ml), dried (MgSO₄), and evaporated. FC (AcOEt/pentane 1:1) gave 3.76 g (65%) of **11b** as a 1:1 diastereoisomer mixture. Colourless foam. IR (KBr): 3470, 2960, 2860, 1690, 1470, 1360, 1280, 1250, 1200, 1100, 1060, 970, 840, 780. ¹H-NMR (CDCl₃): diastereoisomer a: 0.08 (*s*, MeSi); 0.09 (*s*, MeSi); 0.90 (*s*, *t*-BuSi); 1.00 (*s*, *t*-BuC); 1.93 (*d*, $J = 1.2$, Me–C(5)); 2.15 (*ddd*, $J = 3.9$, 6.8, 13.4, H_a–C(2')); 2.36 (*ddd*, $J = 6.7$, 6.8, 13.4, H_b–C(2')); 2.72 (*d*, $J = 8.0$, OH–C(5')); 3.33 (*d*, $J = 8.0$, H–C(5')); 3.98 (*d*, $J = 3.8$, H–C(4')); 4.44 (*dt*, $J = 4.0$, 6.7, H–C(3')); 6.10 (*t*, $J = 6.8$, H–C(1')); 7.43 (*q*, $J = 1.2$, H–C(6)); 8.26 (*s*, NH); diastereoisomer b: 0.09 (*s*, MeSi); 0.10 (*s*, MeSi); 0.90 (*s*, *t*-BuSi); 1.01 (*s*, *t*-BuC); 1.93 (*d*, $J = 1.2$, Me–C(5)); 2.14 (*m*, H_a–C(2')); 2.37 (*m*, H_b–C(2')); 2.83 (*d*, $J = 3.8$, OH–C(5')); 3.50 (*m*, H–C(5')); 4.07 (*t*, $J = 2.2$, H–C(4')); 4.61 (*td*, $J = 2.1$, 5.7, H–C(3')); 6.09 (*dd*, $J = 5.8$, 8.7, H–C(1')); 7.32 (*d*, $J = 1.2$, H–C(6)); 8.22 (*s*, NH). ¹³C-NMR (CDCl₃): diastereoisomer a: –4.7 (MeSi); –4.6 (MeSi); 12.5 (*Me*–C(5)); 18.0 (Me₃CSi); 25.8, 26.5 (Me₃CSi, Me₃CC); 35.2 (Me₃C); 39.7 (C(2')); 74.3 (C(5')); 78.3 (C(3')); 86.2 (C(1')); 87.1 (C(4')); 111.0 (C(5)); 137.4 (C(6)); 150.6 (C(2)); 164.1 (C(4)); diastereoisomer b: –4.9 (MeSi); –4.0 (MeSi); 12.4 (*Me*–C(5)); 17.9 (Me₃CSi); 25.7, 26.4 (Me₃CSi, Me₃CC); 34.3 (Me₃C); 40.7 (C(2')); 72.4 (C(5')); 80.5 (C(3')); 86.0 (C(1')); 88.7 (C(4')); 110.9 (C(5)); 136.9 (C(6)); 150.4 (C(2)); 164.0 (C(4)). FAB-MS: 413 (14, $[M + 1]^+$). Anal. calc. for C₂₀H₃₆N₂O₅Si (412.61): C 58.22, H 8.79, N 6.79; found: C 57.86, H 8.78, N 6.79.

J-{3'-O-[(*tert*-Butyl)dimethylsilyl]-2'-deoxy-5'-C-phenyl- β -D-erythro-pentos-5'-ulofuranosyl}thymine (**12a**). To a soln. of trifluoroacetic anhydride (0.30 ml, 2.23 mmol) in CH₂Cl₂ (5 ml), DMSO (0.30 ml, 4.14 mmol) in CH₂Cl₂ (4 ml) was added dropwise at -60°. The mixture was stirred for 30 min at -60°. A soln. of **11a** (0.27 g, 0.62 mmol) in CH₂Cl₂ (10 ml) was added slowly. Agitation for 1 h at -60° was followed by the addition of Et₃N (0.5 ml, 165 mmol). The mixture was diluted with CH₂Cl₂ (20 ml), hydrolyzed with sat. aq. NaHCO₃ soln. (50 ml), extracted with CH₂Cl₂ (4 × 75 ml), dried (MgSO₄), and evaporated. FC (pentane/Et₂O/CH₂Cl₂ 3:3:4) yielded 0.23 g (85%) of **12a**. Colourless foam. IR (KBr): 3326, 3185, 3065, 2954, 2923, 2855, 1695, 1472, 1278, 1218, 1133, 1085, 982, 837, 777, 692. ¹H-NMR (CDCl₃): 0.08 (s, MeSi); 0.95 (s, *t*-BuSi); 2.02 (s, Me-C(5)); 2.11 (ddd, *J* = 3.5, 8.8, 11.6, H_a-C(2'')); 2.35 (dd, *J* = 5.4, 11.6, H_b-C(2'')); 4.57 (m, H-C(3'')); 5.45 (dd, *J* = 1.4, H-C(4'')); 6.59 (dd, *J* = 5.4, 8.8, H-C(1'')); 7.55 (*t*, *J* = 7.7, H_m); 7.68 (*t*, *J* = 7.1, H_p); 8.02 (*d*, *J* = 7.2, H_o); 8.23 (s, H-C(6)); 9.24 (s, NH). ¹³C-NMR (CDCl₃): -5.0 (MeSi); -4.6 (MeSi); 12.7 (Me-C(5)); 17.8 (Me₃CSi); 25.6 (Me₃CSi); 40.0 (C(2'')); 74.6 (C(3'')); 86.1, 87.6 (C(1'), C(4'')); 111.2 (C(5)); 128.5–134.5 (arom. C); 136.2 (C(6)); 150.4 (C(2)); 163.8 (C(4)); 197.0 (PhCO). FAB-MS: 431 (31, [*M* + 1]⁺). Anal. calc. for C₂₂H₃₀N₂O₅Si (430.59): C 61.37, H 7.02, N 6.51; found: C 61.05, H 7.12, N 6.36.

I-{3'-O-[(*tert*-Butyl)dimethylsilyl]-2',6',7'-trideoxy-6',6'-di-C-methyl- β -D-erythro-heptos-5'-ulofuranosyl}thymine (**12b**). To a soln. of trifluoroacetic anhydride (4.22 ml, 30.0 mmol) in CH₂Cl₂ (200 ml), DMSO (3.63 ml, 50.3 mmol) was added dropwise at -65°. The mixture was stirred for 45 min at -65°. A soln. of **11b** (3.76 g, 9.10 mmol) in CH₂Cl₂ (150 ml) was added slowly. After stirring for another 4 h at -65°, Et₃N (15 ml, 165 mmol) was added. The mixture was diluted with CH₂Cl₂ (500 ml), poured onto 5% aq. tartaric acid soln. (500 ml), extracted with CH₂Cl₂ (2 × 500 ml), dried (MgSO₄), and evaporated. FC (*t*-BuOMe/hexane 1:1) gave 3.35 g (90%) of **12b**. Colourless foam. $[\alpha]_D^{25} = +85.2$ (*c* = 0.011, CHCl₃). IR (KBr): 3180, 3064, 2960, 2930, 2860, 1710, 1470, 1280, 1080, 1050, 830, 780. ¹H-NMR (CDCl₃): 0.07 (s, MeSi); 0.09 (s, MeSi); 0.90 (s, *t*-BuSi); 1.21 (s, *t*-BuC); 1.96 (*d*, *J* = 1.1, Me-C(5)); 2.07 (ddd, *J* = 4.5, 8.8, 13.3, H_a-C(2'')); 2.23 (ddd, *J* = 1.9, 5.2, 13.3, H_b-C(2'')); 4.33–5.35 (*m*, H-C(3'')); 4.84 (*d*, *J* = 1.6, H-C(4'')); 6.51 (dd, *J* = 5.2, 8.8, H-C(1'')); 7.96 (*q*, *J* = 1.1, H-C(6)); 9.31 (s, NH). ¹³C-NMR (CDCl₃): -5.0 (MeSi); -4.9 (MeSi); 12.7 (Me-C(5)); 17.7 (Me₃CSi); 25.6, 25.7 (Me₃CSi, Me₃C); 39.8 (C(2'')); 43.8 (Me₃C); 74.3 (C(3'')); 85.0, 85.4 (C(1'), C(4'')); 111.3 (C(5)); 136.1 (C(6)); 150.6 (C(2)); 164.0 (C(4)); 213.6 (*t*-BuCO). FAB-MS: 411 (13, [*M* + 1]⁺). Anal. calc. for C₂₀H₃₄N₂O₅Si (410.59): C 58.51, H 8.35, N 6.82; found: C 58.59, H 8.33, N 6.46.

I-(2'-Deoxy-5'-C-phenyl- β -D-erythro-pentos-5'-ulofuranosyl)thymine (**13a**). A soln. of **12a** (0.15 g, 0.36 mmol) in THF (10 ml) was treated with 1M Bu₄NF (0.40 ml, 0.40 mmol) in THF at 0°. After stirring for 45 min at 0°, the mixture was directly chromatographed without previous workup. FC (CH₂Cl₂/MeOH 20:1) gave 0.10 g (89%) of **13a**. Colourless foam. IR (KBr): 3378, 3229, 3063, 2926, 1692, 1664, 1474, 1275, 848, 778, 695. ¹H-NMR (CDCl₃ + 10% CD₃OD): 1.93 (s, Me-C(5)); 2.01 (ddd, *J* = 2.8, 5.0, 13.6, H_a-C(2'')); 2.46 (dd, *J* = 9.3, 13.6, H_b-C(2'')); 4.59 (m, H-C(3'')); 5.52 (*d*, *J* = 1.1, H-C(4'')); 6.58 (dd, *J* = 5.0, 9.3, H-C(1'')); 7.55 (dd, *J* = 7.3, 7.6, H_m); 7.68 (*t*, *J* = 7.4, H_p); 8.02 (*d*, *J* = 7.2, H_o); 8.37 (s, H-C(6)). ¹³C-NMR (CDCl₃ + 10% CD₃OD): 12.3 (Me-C(5)); 39.0 (C(2'')); 73.5 (C(3'')); 86.0, 87.5 (C(1'), C(4'')); 111.0 (C(5)); 128.1–134.3 (arom. C); 136.6 (C(6)); 150.8 (C(2)); 164.5 (C(4)); 197.1 (PhCO). FAB-MS: 317 (15, [*M* + 1]⁺). Anal. calc. for C₁₆H₁₆N₂O₅ (316.32): C 60.75, H 5.10, N 8.86; found: C 61.19, H 5.48, N 8.55.

I-(2',6',7'-Trideoxy-6',6'-di-C-methyl- β -D-erythro-heptos-5'-ulofuranosyl)thymine (**13b**). A soln. of **12b** (0.40 g, 0.98 mmol) in THF (4 ml) was treated with 1M Bu₄NF (1.20 ml, 1.20 mmol) in THF at 0°. After stirring for 30 min at 0°, the mixture was directly chromatographed without previous workup. FC (CH₂Cl₂/MeOH 19:1) gave 0.27 g (94%) of **13b**. Colourless foam. $[\alpha]_D^{25} = +76.0$ (*c* = 0.011, MeOH). IR (KBr): 3410, 3230, 3080, 2970, 1720, 1660, 1470, 1300, 1270, 1050. ¹H-NMR (CD₃OD): 1.23 (s, *t*-BuC); 1.92 (*d*, *J* = 1.2, Me-C(5)); 2.04 (ddd, *J* = 5.0, 9.2, 13.5, H_a-C(2'')); 2.26 (ddd, *J* = 1.4, 5.2, 13.5, H_b-C(2'')); 4.39 (*m*, H-C(3'')); 4.96 (*d*, *J* = 1.3, H-C(4'')); 6.47 (dd, *J* = 5.2, 9.3, H-C(1'')); 8.28 (*q*, *J* = 1.2, H-C(6)). ¹³C-NMR (CD₃OD): 12.7 (Me-C(5)); 26.2 (Me₃C); 40.0 (C(2'')); 44.8 (Me₃C); 74.4 (C(3'')); 86.8, 86.9 (C(1'), C(4'')); 111.7 (C(5)); 138.4 (C(6)); 152.5 (C(2)); 166.3 (C(4)); 215.5 (*t*-BuCO). FAB-MS: 297 (37, [*M* + 1]⁺). Anal. calc. for C₁₄H₂₀N₂O₅ (296.33): C 56.75, H 6.80, N 9.45; found: C 56.17, H 6.88, N 9.02.

4'-C-Benzoylthymidine (**10c**), *I*-(4'-C-Benzoyl-2'-deoxy- α -L-threo-pentofuranosyl)thymine (**14a**), and *I*-(4'-C-Benzoyl-2'-deoxy- β -D-threo-pentofuranosyl)thymine (**15**). Ba(OH)₂ · 8 H₂O (0.12 g, 0.68 mmol) was suspended in a soln. of **13a** (0.18 g, 0.56 mmol) in dioxane/H₂O 10:1 (3.6 ml). After addition of 36% aq. formaldehyde soln. (0.30 ml, 3.60 mmol), the mixture was sonicated for 30 s (sonication bath). Stirring at 25° was continued for 1 h. The mixture was frozen with liquid N₂ and lyophilized *in vacuo*. FC (CH₂Cl₂/MeOH 2:1) of the white residue gave 38 mg (22%) of **15** and 126 mg (73%) of **14a/10c** (2.5:1). Prep. HPLC (Knauer; RP-18, 7 μ m; column 250 × 15 mm; flow 6 ml/min; H₂O/MeCN 81:19) gave 38 mg (22%) of **10c** and 72 mg (42%) of **14a** as a colourless solid.

Data for 10c: IR (KBr): 3442, 3065, 2935, 1692, 1633, 1512, 1469, 1282, 1256, 1141, 1042, 953, 752. ¹H-NMR ((D₆)DMSO): 1.78 (*d*, *J* = 1.0, Me–C(5)); 2.16 (*dd*, *J* = 5.5, 12.9, H_a–C(2')); 2.29 (*ddd*, *J* = 4.9, 9.6, 13.0, H_b–C(2')); 3.85 (*dd*, *J* = 5.5, 11.6, H_a–C(5')); 3.86 (*dd*, *J* = 5.5, H_b–C(5')); 4.55 (*t*, *J* = 4.5, H–C(3')); 5.35 (*t*, *J* = 5.4, OH–C(5')); 5.70 (*d*, *J* = 4.4, OH–C(3')); 6.44 (*dd*, *J* = 5.3, 9.6, H–C(1')); 7.44 (*t*, *J* = 7.9, H_m); 7.52 (*tt*, *J* = 1.3, 7.4, H_p); 7.76 (*dd*, *J* = 1.3, 7.2, H_a); 7.80 (*q*, *J* = 1.2, H–C(6)); 11.32 (*s*, NH); NOE H–C(6) → H–C(5') (+), H–C(1') (++)); H_o → H–C(5') (+), H–C(1') (++)); H–C(1') → H_o (+), H–C(6) (+); H–C(3') → H–C(5') (+); H–C(5') → H_o (+), H–C(6) (+), H–C(3') (+); H_a–C(2') → H–C(6) (+). ¹³C-NMR ((D₆)DMSO): 12.3 (Me–C(5)); 40.1 (C(2')); 65.3 (C(5')); 74.2 (C(3')); 85.1 (C(1')); 97.6 (C(4')); 109.5 (C(5)); 127.8 (C_m); 128.4 (C_o); 131.5 (C_p); 136.0 (C(6)); 138.3 (C_{ipso}); 150.5 (C(2)); 163.7 (C(4)); 202.3 (PhCO). FAB-MS: 347 (33, [M + 1]⁺). Anal. calc. for C₁₇H₁₈N₂O₆ · 0.75 H₂O (359.85): C 56.67, H 5.60, N 7.78; found: C 56.61, H 5.54, N 7.74.

Data for 14a: IR (KBr): 3454, 3041, 2899, 1701, 1687, 1537, 1470, 1460, 1285, 1049, 953, 752, 672. ¹H-NMR ((D₆)DMSO): 1.36 (*s*, Me–C(5)); 1.99 (*ddd*, *J* = 5.1, 9.0, 13.5, H_a–C(2')); 2.04 (*ddd*, *J* = 2.1, 5.8, 13.5, H_b–C(2')); 3.84 (*dd*, *J* = 4.1, 11.6, H_a–C(5')); 4.00 (*dd*, *J* = 5.7, 11.6, H_b–C(5')); 4.75 (*m*, H–C(3')); 5.13 (*m*, OH); 5.75 (*m*, OH); 6.39 (*dd*, *J* = 5.8, 9.0, H–C(1')); 6.59 (*s*, H–C(6)); 7.44 (*t*, *J* = 6.9, H_m); 7.56 (*t*, *J* = 7.3, H_p); 7.92 (*d*, *J* = 7.1, H_a); 11.2 (*s*, NH); NOE H_o → H–C(6) (+); H–C(6) → H–C(3') (+), H_o (++)); H–C(1') (++)); H–C(1') → H–C(5') (++)); H–C(3') → H–C(6) (++)); H–C(5') → H_o (+), H–C(1') (++)); OH–C(3') (+). ¹³C-NMR ((D₆)DMSO): 12.1 (Me–C(5)); 38.2 (C(2')); 64.7 (C(5')); 74.5 (C(3')); 84.9 (C(1')); 97.0 (C(4')); 108.9 (C(5)); 127.7–135.7 (arom. C); 135.6 (C(6)); 150.5 (C(2)); 163.4 (C(4)); 203.7 (PhCO). FAB-MS: 347 (32, [M + 1]⁺). Anal. calc. for C₁₇H₁₈N₂O₆ · 0.75 H₂O (359.85): C 56.67, H 5.60, N 7.78; found: C 56.55, H 5.68, N 7.71.

Data for 15: IR (KBr): 3418, 3066, 2929, 1685, 1473, 1285, 1104, 1052, 786, 693. ¹H-NMR (CDCl₃ + 10% CD₃OD): 1.95 (*s*, Me–C(5)); 2.06 (*ddd*, *J* = 2.6, 3.9, 14.8, H_a–C(2')); 2.49 (*ddd*, *J* = 5.8, 8.0, 14.8, H_b–C(2')); 4.21 (*d*, *J* = 11.8, H_a–C(5')); 4.29 (*d*, *J* = 11.8, H_b–C(5')); 4.94 (*dd*, *J* = 2.6, 5.8, H–C(3')); 6.07 (*dd*, *J* = 3.9, 8.0, H–C(1')); 7.45 (*dd*, *J* = 7.7, 8.0, H_m); 7.56 (*t*, *J* = 7.5, H_p); 7.95 (*s*, H–C(6)); 8.12 (*d*, *J* = 7.2, H_a); NOE H_o → H–C(5') (+), H–C(1') (++)); H–C(6) → H–C(5') (+), H–C(1') (++)); H–C(1') → H_o (+), H–C(6) (+); H–C(3') → H_o (++)); H–C(1') (++)); H–C(5') → H_o (+), H–C(6) (++)); H_b–C(2') → H–C(5') (+). ¹³C-NMR (CDCl₃ + 10% CD₃OD): 12.5 (Me–C(5)); 40.1 (C(2')); 63.9 (C(5')); 72.4 (C(3')); 83.2 (C(1')); 98.2 (C(4')); 109.3 (C(5)); 128.1–136.2 (arom. C); 136.8 (C(6)); 150.4 (C(2)); 163.6 (C(4)); 195.3 (PhCO). FAB-MS: 347 (59, [M + 1]⁺). Anal. calc. for C₁₇H₁₈N₂O₆ · 1 H₂O (364.35): C 57.64, H 5.39, N 7.88; found: C 57.13, H 5.85, N 7.21.

4'-C-(2,2-Dimethylpropanoyl)thymidine (10d) and 1-(2'-Deoxy-4'-C-(2,2-dimethylpropanoyl)-α-L-threo-pentofuranosyl)thymine (14b). Ba(OH)₂ · 8 H₂O (0.18 g, 0.57 mmol) was suspended in a soln. of **13b** (0.32 g, 1.10 mmol) in dioxane (7 ml). After addition of H₂O (1 ml), a 36% aq. formaldehyde soln. (0.40 ml, 5.20 mmol) was added. Stirring at 25° was continued for 12 h. The mixture was quenched with a sat. aq. NH₄Cl soln. (15 ml), extracted with AcOEt (3 × 10 ml), dried (MgSO₄), and evaporated. MPLC (AcOEt/pentane/MeOH 15:3:0.4) gave 0.23 g (65%) of **10d** as a colourless solid (see above) and 0.07 g (21%) of **14b**. **14b:** M.p. 221–223°. ¹H-NMR (CD₃OD): 1.17 (*s*, *t*-BuC); 1.89 (*d*, *J* = 1.2, Me–C(5)); 2.44 (*m*, H–C(2')); 3.85 (*d*, *J* = 12.1, H_a–C(5')); 3.97 (*d*, *J* = 12.1, H_b–C(5')); 4.68 (*t*, *J* = 7.7, H–C(3')); 6.28 (*dd*, *J* = 5.1, 8.0, H–C(1')); 7.55 (*q*, *J* = 1.2, H–C(6)). ¹³C-NMR (CD₃OD): 12.4 (Me–C(5)); 27.0 (Me₃C); 37.6 (C(2')); 46.1 (Me₃C); 64.6 (C(5')); 74.6 (C(3')); 85.8 (C(1')); 96.8 (C(4')); 112.1 (C(5)); 139.5 (C(6)); 152.8 (C(2)); 166.8 (C(4)); 217.3 (*t*-BuCO). Anal. calc. for C₁₅H₂₂N₂O₆ · 1.0 H₂O (344.35): C 52.27, H 8.13; found: C 52.48, H 6.64, N 7.89.

X-Ray Structure Analyses of 10d, 14b, and 15 (see Figs. 1 and 2). Unit-cell parameters were determined by accurate centering of 25 strong independent reflections by the least-squares method. Reflection intensities were collected at r.t. on a four-circle diffractometer *Enraf-Nonius CAD4* equipped with a graphite monochromator and using CuK_α radiation. Three standard reflections monitored every 2 h during data collection showed no significant loss in intensity. The absorption profiles were measured for the correction of the absorptions. The usual corrections were applied and the structures solved by direct-method strategies using the program SIR92 [22]. Anisotropic least-squares refinement was carried out on all non-H-atoms using the program CRYSTALS [23]. Scattering factors were taken from the International Tables of Crystallography, Vol. IV [24]. The H-atoms attached to N/O atoms (N–H and O–H) were fixed at a distance of 0.96 Å and were isotropically refined. Fractional coordinates are deposited in the *Cambridge Crystallographic Data Base*. In the unit-cell of structure **10d**, one finds 4 symmetry-dependent units and 1 H₂O molecule. This H₂O molecule makes higher symmetry impossible. There is a considerable number of H-bondings between molecules **10d** themselves and with the H₂O molecule.

Separation of 10c/14a: 1-(4'-C-benzoyl-2'-deoxy-3',5'-O-isopropylidene-α-L-threo-pentofuranosyl)thymine (**16**). A 3:1 diastereoisomer mixture **14a/10c** (100 mg, 0.29 mmol) and TsOH · H₂O (50 mg, 0.26 mmol) were dissolved in acetone (20 ml) and stirred 16 h at r.t. The mixture was concentrated to 5 ml *in vacuo*. FC (pentane/acetone 1:1) yielded 71 mg (98%) of **16** and 31.5 mg (90%) of unreacted **10c** as colourless glasses. **16:** IR (KBr): 3422, 3051, 2931, 1685, 1475, 1386, 1142, 1105, 1055, 771, 695. ¹H-NMR (CDCl₃): 1.43 (*s*, 3 H, Me₂C); 1.46

(s, 3 H, Me₂C); 1.53 (s, Me–C(5)); 1.94 (m, H–C(2')); 4.15 (d, *J* = 11.8, H_a–C(5')); 4.23 (d, *J* = 11.8, H_b–C(5')); 5.19 (d, *J* = 4.1, H–C(3')); 6.43 (s, H–C(6)); 6.68 (dd, *J* = 4.0, 5.2, H–C(1')); 7.48 (t, *J* = 6.5, H_m); 7.56 (t, *J* = 6.1, H_p); 8.12 (d, *J* = 6.2, H_o). ¹³C-NMR (CDCl₃): 12.2 (Me–C(5)); 20.7, 26.9 (Me₂C); 37.1 (C(2')); 64.6 (C(5')); 72.8 (C(3')); 87.7 (C(1')); 89.0, 98.7 (Me₂C, C(4')); 111.1 (C(5)); 128.4, 128.7 (C_m, C_n); 130.0 (C_p); 133.9 (C(6)); 137.1 (C_{psa}); 150.1 (C(2)); 163.7 (C(4)); 199.0 (PhCO). FAB-MS: 387 (22, [M + 1]⁺). Anal. calc. for C₂₀H₂₂N₂O₆ (386.38): C 62.01, H 5.98, N 7.22; found: C 61.70, H 5.91, N 7.02.

Isomerization of 15. Ba(OH)₂ · 8 H₂O (3.1 mg, 0.016 mmol) was suspended in a soln. of **15** (5 mg, 0.014 mmol) in dioxane/H₂O 10:1 (1.0 ml), and the mixture was sonicated for 30 s. Stirring at 25° was continued for 1 h. The mixture was diluted with acetone/H₂O 1:1 (1.0 ml) and analyzed by HPLC (Merck RP-18, 5 μm; column 250 × 4 mm; flow 1 ml/min; H₂O/MeCN 95:5 → 40:60). Comparison with authentic material showed that the mixture contained isomers **10c**, **14a**, and **15**. A quantitative analysis was not carried out.

General Procedure for the Preparation of the 4'-C-Acyl-5'-O-(4,4'-dimethoxytrityl)thymidines (17). A mixture of **10**, 4,4'-dimethoxytrityl chloride (2 equiv.) and a catal. amount of 4-(dimethylamino)pyridine was stirred (4 ml/mmol **10**) at 25° for 24 h. After the reaction was completed, MeOH (1 ml/mmol) was added. The mixture was poured onto sat. aq. NaHCO₃ soln. (100 ml/mmol) and extracted with CH₂Cl₂ (3 × 50 ml), dried (MgSO₄), and evaporated. FC gave **17** as a pale yellow foam.

4'-C-Acetyl-5'-O-(4,4'-dimethoxytrityl)thymidine (17a). Compound **10a** (0.70 g, 2.46 mmol) was converted into 1.47 g (90%) **17a**, after FC (AcOEt/pentane/Et₃N 1:1:0.01). IR (KBr): 3447, 3064, 2955, 1688, 1607, 1509, 1465, 1297, 1177, 1092, 1034, 830. ¹H-NMR (CDCl₃): 1.42 (s, Me–C(5)); 2.30 (MeCO); 2.43 (m, H–C(2')); 3.12 (s, OH–C(3')); 3.42 (d, *J* = 9.9, H_a–C(5')); 3.55 (d, *J* = 9.9, H_b–C(5')); 3.79 (s, MeO); 4.65 (d, *J* = 3.8, H–C(3')); 6.68 (dd, *J* = 5.7, 8.9, H–C(1')); 6.84 (m, arom. H); 7.30 (m, arom. H); 7.56 (s, H–C(6)); 9.20 (s, NH). ¹³C-NMR (CDCl₃): 11.7 (Me–C(5)); 28.7 (MeCO); 40.1 (C(2')); 55.3 (MeO); 66.4 (C(5')); 75.0 (C(3')); 86.0 (C(1')); 87.6 (Ar₃C); 95.7 (C(4')); 111.7 (C(5)); 113.4 (C_m of MeOC₆H₄); 127.3–144.0 (arom. C, C(6)); 150.5 (C(2)); 158.9 (C_p of MeOC₆H₄); 163.8 (C(4)); 211.6 (MeCO). FAB-MS: 587 (2, [M + 1]⁺). Anal. calc. for C₃₃H₃₄N₂O₈ (586.65): C 67.56, H 5.84, N 4.78; found: C 67.22, H 6.37, N 4.29.

4'-C-Benzoyl-5'-O-(4,4'-dimethoxytrityl)thymidine (17b). Compound **10c** (38 mg, 0.109 mmol) was converted into 56 mg (80%) of **17b**, after FC (AcOEt/pentane/Et₃N 1:3:0.01). IR (KBr): 3392, 3059, 2954, 2835, 1685, 1607, 1508, 1465, 1446, 1278, 1251, 1177, 1074, 1033, 829, 696. ¹H-NMR (CDCl₃): 1.50 (s, Me–C(5)); 2.40 (m, H–C(2')); 3.55 (d, *J* = 9.9, H_a–C(5')); 3.69 (d, *J* = 9.9, H_b–C(5')); 3.78 (s, MeO); 4.75 (dd, *J* = 1.9, 3.6, H–C(3')); 6.51 (dd, *J* = 5.7, 8.8, H–C(1')); 6.79–7.45 (m, arom. H); 7.50 (s, H–C(6)); 7.96 (d, *J* = 6.2, H_p). ¹³C-NMR (CDCl₃): 11.9 (Me–C(5)); 39.1 (C(2')); 55.2 (MeO); 67.6 (C(5')); 75.6 (C(3')); 85.8 (C(1')); 87.9 (Ar₃C); 95.9 (C(4')); 111.4 (C(5)); 113.3 (C_m of MeOC₆H₄); 127.2–143.8 (arom. C); 135.4 (C(6)); 150.2 (C(2)); 158.7 (C_p of MeOC₆H₄); 163.6 (C(4)); 202.8 (PhCO). FAB-MS: 648 (1.7, [M + 1]⁺). Anal. calc. for C₃₈H₃₆N₂O₈ · 0.5 H₂O (657.72): C 69.12, H 5.62, N 4.26; found: C 69.02, H 5.55, N 4.18.

5'-O-(4,4'-Dimethoxytrityl)-4'-C-(2,2-dimethylpropanoyl)thymidine (17c). Compound **10d** (0.48 g, 1.46 mmol) was converted into 0.77 g (85%) of **17c**, after FC (AcOEt/pentane/Et₃N 1:3:0.01). [α]_D²⁵ = –2.0 (c = 0.011, CHCl₃). IR (KBr): 3450, 3060, 2960, 2930, 1690, 1610, 1510, 1470, 1250, 1180, 1110, 1030, 830. ¹H-NMR (CDCl₃): 1.16 (s, *t*-BuC); 1.26 (d, *J* = 1.2, Me–C(5)); 2.43 (m, H–C(2')); 2.83 (br. s, OH–C(3')); 3.44 (m, H–C(5')); 3.79 (s, MeO); 4.67 (d, *J* = 4.2, H–C(3')); 6.70 (dd, *J* = 5.4, 9.7, H–C(1')); 6.83 (m, arom. H); 7.29 (m, arom. H); 7.64 (s, H–C(6)); 9.21 (s, NH). ¹³C-NMR (CDCl₃): 11.3 (Me–C(5)); 25.9 (Me₂C); 38.8 (C(2')); 45.7 (Me₃C); 55.2 (Me₂C); 68.2 (C(5')); 76.1 (C(3')); 85.4 (C(1')); 88.0 (Ar₃C); 98.7 (C(4')); 111.4 (C(5)); 113.3 (C_m of MeOC₆H₄); 127.4–143.6 (arom. C); 135.8 (C(6)); 150.5 (C(2)); 158.8 (C_p of MeOC₆H₄); 163.9 (C(4)); 217.1 (*t*-BuCO). FAB-MS: 629 (2, [M + 1]⁺). Anal. calc. for C₃₆H₄₀N₂O₈ (628.42): C 68.77, H 6.41, N 4.46; found: C 68.41, H 6.67, N 4.74.

General Procedure for the Preparation of the 3'-O-Phosphoramidites 3. Compound **17**, (i-Pr)₂EtN (5.5 equiv.), and 2-cyanoethyl *N,N*-diisopropylphosphorochloridamide (2.3 equiv.) were dissolved in CH₂Cl₂ (4 ml/mmol **17**) and stirred for 2 h at 25°. The mixture was diluted with CH₂Cl₂ (20 ml), hydrolyzed with sat. aq. NaHCO₃ soln. (100 ml/mmol), extracted with CH₂Cl₂ (2 × 50 ml), dried (MgSO₄), and evaporated. FC gave **3** as a pale yellow foam.

4'-C-Acetyl-5'-O-(4,4'-dimethoxytrityl)thymidine 3'-O-[(2-Cyanoethyl) N,N-Diisopropylphosphoramidite] (3a). Compound **17a** (0.50 g, 0.85 mmol) was converted into 0.62 g (92%) of **3a**, after FC (AcOEt/pentane/Et₃N 2:1:0.01). IR (KBr): 3447, 3059, 2967, 2931, 1700, 1654, 1509, 1509, 1466, 1252, 1179, 1032, 831. ¹H-NMR (CDCl₃; diastereoisomer mixture): 1.25 (m, Me₂CH, Me–C(5)); 2.45 (m, H–C(2'), CH₂CN, MeCO); 3.60 (m, CH₂OP, Me₂CH, H–C(5'), 2 MeO); 4.76 (m, H–C(3')); 6.66 (m, H–C(1')); 6.85 (m, arom. H); 7.31 (m, arom. H); 7.58, 7.60 (2q, *J* = 1.0, H–C(6)). ¹³C-NMR (CDCl₃; diastereoisomer mixture): 11.7 (Me–C(5)); 20.3–20.5 (CH₂CN); 24.3–24.7 (Me₂CH); 28.6 (MeCO); 39.7 (C(2')); 43.4, 43.6 (2d, *J* = 12.4(a), 12.5(b), Me₂CH); 55.3 (MeO); 58.0, 58.66 (2d, *J* = 20.4(a), 19.0(b), CH₂OP); 65.9, 66.0 (C(5')); 76.8 (C(3')); 86.0, 86.1 (C(1')); 87.6 (Ar₃C); 94.4

(*d*, *J* = 5.8, C(4')); 111.5 (C(5)); 113.4 (*C_m* of MeOC₆H₄); 117.5 (CN); 127.3–144.0 (arom. C, C(6)); 150.3 (C(2)); 158.9 (*C_p* of MeOC₆H₄); 163.8 (C(4)); 208.0, 208.2 (MeCO). ³¹P-NMR (CDCl₃): 150.1 (diastereoisomer a); 150.0 (diastereoisomer b). FAB-MS: 787 (2, [*M* + 1]⁺). Anal. calc. for C₄₂H₅₁N₄O₉P · 0.5 H₂O (795.87): C 63.32, H 6.52, N 7.00; found: C 62.97, H 6.50, N 6.85.

4'-*C*-Benzoyl-5'-*O*-(4,4'-dimethoxytrityl)thymidine 3'-*O*-[(2-Cyanoethyl) N,N-Diisopropylphosphoramidite] (**3b**). Compound **17b** (50 mg, 0.077 mmol) was converted into 50 mg (76%) **3b**, after FC (AcOEt/pentane/Et₃N 2:1:0.01). IR (KBr; diastereoisomer mixture): 3177, 3066, 2966, 1686, 1605, 1511, 1466, 1250, 1177, 1122, 1072, 1033, 828, 755, 700. ¹H-NMR (CDCl₃): diastereoisomer a: 1.17 (*m*, Me₂CH); 1.48 (*s*, Me–C(5)); 2.42 (*m*, CH₂CN); 2.65 (*dd*, *J* = 5.0, 13.2, H_a–C(2')); 2.78 (*dd*, *J* = 3.7, 13.2, H_b–C(2')); 3.45 (*m*, CH₂OP, Me₂CH, H–C(5'), MeO); 4.90 (*dd*, *J* = 4.6, 8.8, H–C(3')); 6.60 (*dd*, *J* = 3.7, 5.0, H–C(1')); 6.83 (*m*, arom. H); 7.12–7.52 (*m*, arom. H); 7.66 (*s*, H–C(6)); 7.82 (*d*, *J* = 6.2, H_o); 8.67 (*s*, NH); diastereoisomer b: 1.17 (*m*, Me₂CH); 1.55 (*s*, Me–C(5)); 2.37 (*m*, CH₂CN, H–C(2')); 3.61 (*m*, CH₂OP, Me₂CH, H–C(5'), MeO); 5.00 (*dd*, *J* = 4.1, 11.9, H–C(3')); 6.48 (*dd*, *J* = 2.3, 7.7, H–C(1')); 6.75 (*m*, arom. H); 7.14–7.61 (*m*, arom. H); 7.62 (*s*, H–C(6)); 8.09 (*d*, *J* = 7.3, H_o); 8.67 (*s*, NH). ¹³C-NMR (CDCl₃): diastereoisomer a: 11.7 (Me–C(5)); 20.2 (*d*, *J* = 7.1, CH₂CN); 24.1 (*d*, *J* = 7.0, Me₂CH); 24.4 (*d*, *J* = 7.0, Me₂CH); 39.3 (br. C(2')); 43.5 (*d*, *J* = 12.5, Me₂CH); 55.2 (MeO); 58.5 (*d*, *J* = 18.9, CH₂OP); 67.3 (C(5')); 77.5 (*d*, *J* = 18.9, C(3')); 85.8 (C(1')); 87.7 (Ar₃C); 96.2 (*d*, *J* = 6.1, C(4')); 112.9 (C(5)); 113.3 (*C_m* of MeOC₆H₄); 117.5 (CN); 127.1–143.9 (arom. C); 135.7 (C(6)); 150.2 (C(2)); 158.7 (*C_p* of MeOC₆H₄); 163.7 (C(4)); 195.5 (PhCO); diastereoisomer b: 12.4 (Me–C(5)); 19.9 (*d*, *J* = 7.8, CH₂CN); 24.2 (*d*, *J* = 7.2, Me₂CH); 24.4 (*d*, *J* = 7.2, Me₂CH); 39.7 (br. C(2')); 43.5 (*d*, *J* = 12.9, Me₂CH); 55.2 (MeO); 58.4 (*d*, *J* = 19.1, CH₂OP); 67.3 (C(5')); 77.5 (*d*, *J* = 19.2, C(3')); 85.6 (C(1')); 87.7 (Ar₃C); 96.5 (*d*, *J* = 6.3, C(4')); 111.1 (C(5)); 113.3 (*C_m* of MeOC₆H₄); 117.5 (CN); 127.1–143.9 (arom. C); 135.6 (C(6)); 150.1 (C(2)); 158.4 (*C_p* of MeOC₆H₄); 163.8 (C(4)); 200.1 (PhCO). ³¹P-NMR (CDCl₃): 149.8 (diastereoisomer a); 149.4 (diastereoisomer b). FAB-MS (diastereoisomer mixture): 849 (1.1, [*M* + 1]⁺). Anal. calc. for diastereoisomer mixture C₄₇H₅₃N₄O₉P · H₂O (866.49): C 65.60, H 6.39, N 6.46; found: C 65.57, H 6.42, N 6.61.

5'-*O*-(4,4'-Dimethoxytrityl)-4'-*C*-(2,2-dimethylpropanoyl)thymidine 3'-*O*-[(2-Cyanoethyl) N,N-Diisopropylphosphoramidite] (**3c**). Compound **10d** (0.66 g, 1.05 mmol) was converted into 0.80 g (91%) of **3c**, after FC (AcOEt/pentane/Et₃N 2:3:0.01). IR (KBr): 3420, 3200, 2970, 2930, 1700, 1610, 1510, 1470, 1250, 1180, 1110, 1030, 980, 830, 730. ¹H-NMR (CDCl₃): diastereoisomer a: 1.18 (*s*, *t*-BuC); 1.20 (*m*, Me₂CH); 1.28 (*s*, Me–C(5)); 2.37 (*ddd*, *J* = 4.4, 10.3, 12.8, H_a–C(2')); 2.51 (*dd*, *J* = 4.9, 12.9, H_b–C(2')); 2.58 (*t*, *J* = 6.2, CH₂CN); 3.50 (*m*, H–C(5')); 3.58 (*m*, Me₂CH); 3.74 (*m*, CH₂OP); 3.80 (*s*, MeO); 4.71 (*dd*, *J* = 4.2, *J*(P,H) = 8.6, H–C(3')); 6.61 (*dd*, *J* = 4.8, 10.0, H–C(1')); 6.83 (*m*, arom. H); 7.29 (*m*, arom. H); 7.67 (*q*, *J* = 1.2, H–C(6)); diastereoisomer b: 1.16 (*s*, *t*-BuC); 1.16 (*d*, *J* = 6.6, Me₂CH); 1.23 (*d*, *J* = 1.2, Me–C(5)); 2.57 (*m*, H–C(2')); 2.62 (*t*, *J* = 6.0, CH₂CN); 3.57 (*m*, CH₂OP, Me₂CH, H–C(5')); 3.79 (*s*, MeO); 4.66 (*dd*, *J* = 2.8, 8.8, H–C(3')); 6.66 (*dd*, *J* = 6.1, 9.9, H–C(1')); 6.82 (*d*, *J* = 8.6, arom. H); 7.28 (*m*, arom. H); 7.64 (*q*, *J* = 1.1, H–C(6)). ¹³C-NMR (CDCl₃): diastereoisomer a: 11.3 (Me–C(5)); 20.3–20.4 (CH₂CN); 24.2–24.7 (Me₂CH); 26.0 (Me₃C); 39.2 (C(2')); 43.6 (*d*, *J* = 12.5, Me₂CH); 45.3 (Me₃C); 55.2 (MeO); 59.0 (*d*, *J* = 19.5, CH₂OP); 68.9 (C(5')); 78.7 (*d*, *J* = 24.8, C(3')); 85.6 (C(1')); 88.1 (Ar₃C); 97.5 (*d*, *J* = 8.5, C(4')); 111.2 (C(5)); 113.3 (*C_m* of MeOC₆H₄); 117.6 (CN); 127.3–143.7 (arom. C); 135.8 (C(6)); 150.3 (C(2)); 158.8 (*C_p* of MeOC₆H₄); 163.7 (C(4)); 213.3 (*t*-BuCO); diastereoisomer b: 11.2 (Me–C(5)); 20.4–20.5 (CH₂CN); 24.4–24.7 (Me₂CH); 26.0 (Me₃C); 39.4 (C(2')); 43.2 (*d*, *J* = 12.5, Me₂CH); 45.2 (Me₃C); 55.2 (MeO); 57.9 (*d*, *J* = 24.4, CH₂OP); 68.8 (C(5')); 78.4 (*d*, *J* = 12.7, C(3')); 85.3 (C(1')); 88.0 (Ar₃C); 97.3 (*d*, *J* = 8.0, C(4')); 111.3 (C(5)); 113.3 (*C_m* of MeOC₆H₄); 117.5 (CN); 127.3–143.6 (arom. C); 136.0 (C(6)); 150.5 (C(2)); 158.8 (*C_p* of MeOC₆H₄); 163.7 (C(4)); 213.1 (*t*-BuCO). ³¹P-NMR (CDCl₃): 149.9 (*sext.*, *J* = 8.2, diastereoisomer a); 151.8 (*sext.*, *J* = 8.3, diastereoisomer b). FAB-MS: 829 (2, [*M* + 1]⁺). Anal. calc. for C₄₅H₅₇N₄O₉P (828.37): C 65.21, H 6.93, N 6.76; found: C 64.63, H 7.19, N 6.69.

General Procedure for the Solid-Phase Synthesis of the 4'-Modified Oligonucleotides (5'-3')d(T₄T^{}T₇) (18a–c)*. The synthesis of the oligonucleotides **18** was carried out on an ABI 392 DNA/RNA synthesizer in a 1-μmol scale (20 mol-equiv. of phosphoramidite per cycle, 500 Å controlled-pore glass (CPG) support). A standard procedure for 2-cyanoethyl phosphoramidites was used, except that the coupling time of the modified nucleoside **3** was extended to 30 min. The coupling efficiencies of the modified building blocks **3** were similar to those of the commercially available amidites (98%, assigned by conductivity measurements of the trityl salt released on each cycle). Conc. NH₃ soln. was used to remove the oligonucleotides from the solid support (55°, 8 h). The crude oligonucleotides were detritylated and desalted on oligonucleotide cartridges (OPC, MWG-Biotech). Prep. HPLC (RP-18, linear gradient of 5–40% MeCN (20 min) in 0.1% (Et₃NH)OAc soln. of pH 7.0) led, after lyophilization, to the oligonucleotides **18**. MALDI-TOF-MS: 3629.2 ([*M* – H][–] for **18a**, calc. 3929.6). MALDI-TOF-MS: 3691.8 ([*M* – H][–] for **18b**, calc. 3691.6). MALDI-TOF-MS: 3671.8 ([*M* – H][–] for **18c**, calc. 3671.6).

REFERENCES

- [1] I. H. Goldberg, *Acc. Chem. Res.* **1991**, *24*, 191.
- [2] K. C. Nicolaou, W.-M. Dai, *Angew. Chem. Int. Ed.* **1991**, *30*, 1387.
- [3] J. Stubbe, J. W. Kozarich, *Chem. Rev.* **1987**, *87*, 1107.
- [4] G. Pratiel, J. Bernadou, B. Meunier, *Angew. Chem. Int. Ed.* **1995**, *34*, 746.
- [5] C. von Sonntag, in 'The Chemical Basis of Radiation Biology', Taylor and Francis, London, 1987; D. Schulte-Frohlinde, *Chemie in unserer Zeit* **1990**, *24*, 37.
- [6] B. Giese, P. Erdmann, T. Schäfer, U. Schwitter, *Synthesis* **1994**, 1310; B. Giese, P. Imwinkelried, M. Petretta, *Synlett* **1994**, 1003.
- [7] C. O. Yang, W. Kurz, E. M. Egui, M. J. McRoberts, J. P. H. Verheyden, L. J. Kurz, K. A. M. Walker, *Tetrahedron Lett.* **1992**, *33*, 41.
- [8] C. O. Yang, H. Y. Wu, E. B. Fraser-Smith, K. A. M. Walker, *Tetrahedron Lett.* **1992**, *33*, 37.
- [9] T. V. Lee, in 'Comprehensive Organic Synthesis', Eds. B. M. Trost and I. Fleming, Pergamon Press, Oxford, 1991, Vol. 7, p. 291–303; A. J. Mancuso, D. Swern, *Synthesis* **1981**, 165.
- [10] D. B. Dess, J. C. Martin, *J. Org. Chem.* **1983**, *48*, 4156; D. B. Dess, J. C. Martin, *J. Am. Chem. Soc.* **1991**, *113*, 7277; R. E. Ireland, L. Liu, *J. Org. Chem.* **1993**, *58*, 2899.
- [11] K. C. Nicolaou, S. P. Seitz, M. R. Pavia, *J. Am. Chem. Soc.* **1981**, *103*, 1222.
- [12] T. Imamoto, T. Kusumoto, Y. Tawarayama, Y. Sugiura, T. Mita, Y. Hatanaka, M. Yokoyama, *J. Org. Chem.* **1984**, *49*, 3904; T. Imamoto, Y. Sugiura, N. Takiyama, *Tetrahedron Lett.* **1984**, *25*, 4233.
- [13] T. Imamoto, N. Takiyama, K. Nakamura, T. Hatajima, Y. Kamiya, *J. Am. Chem. Soc.* **1989**, *111*, 4392.
- [14] W. Saenger, in 'Principles of Nucleic Acid Structure', Ed. C. R. Cantor, Springer-Verlag, New York, 1984, p. 20.
- [15] D. W. Young, P. Tollin, H. R. Wilson, *Acta Crystallogr.* **1969**, *25*, 1423.
- [16] C. Altona, M. Sundaralingam, *J. Am. Chem. Soc.* **1973**, *95*, 2333.
- [17] T. Bandyopadhyay, J. Wu, A. S. Seriani, *J. Org. Chem.* **1993**, *58*, 5513.
- [18] C. H. Heathcock, C. T. Buse, W. A. Kleschick, M. C. Pirrung, J. E. Sohn, J. Lampe, *J. Org. Chem.* **1980**, *45*, 1066.
- [19] B. Giese, X. Beyrich-Graf, P. Erdmann, L. Giraud, P. Imwinkelried, S. N. Müller, U. Schwitter, *J. Am. Chem. Soc.* **1995**, *117*, 6146.
- [20] N. D. Sinha, J. Biernat, J. McManus, H. Köster, *Nucleic Acids Res.* **1984**, *12*, 4539.
- [21] J. Stollwerk, in 'Gentechnische Methoden', Ed. S. Bertram and H. G. Gassen, Fischer, Stuttgart, 1991, p. 201.
- [22] A. Altomare, G. Cascarano, G. Giacovazzo, A. Guagliardi, M. C. Burla, G. Polidori, M. Camalli, 'SIR92', *J. Appl. Crystallogr.* **1994**, *27*, 435.
- [23] D. J. Watkin, R. J. Carruthers, P. Betteridge, 'CRYSTALS (1990)', Chemical Crystallography Laboratory, Oxford, UK.
- [24] International Tables for X-Ray Crystallography, Vol. IV, Table 2.2B.